Breast cancers with neuroendocrine differentiation: Retrospective case studies series from a single institution based on the 2019 WHO classification
Background: The World Health Organization's fifth edition of tumor series classification was published in 2019 and adopted the term ‘Neuroendocrine neoplasm (NEN)’ to encompass all tumor classes with predominant neuroendocrine differentiation (NED). Based on the updated classification of the NE...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2024-01-01
|
| Series: | Cancer Treatment and Research Communications |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2468294224000698 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1823864244100136960 |
|---|---|
| author | Youngkyung Jeon Ji-Yeon Kim Jin Seok Ahn Young-Hyuck Im Kyuehee Choi Sun Young Jeong Yeji Jung Jaeyeon Jang Dae-Ho Choi Joohyun Hong Hyo Jung Kim Soo Youn Cho Yeon Hee Park |
| author_facet | Youngkyung Jeon Ji-Yeon Kim Jin Seok Ahn Young-Hyuck Im Kyuehee Choi Sun Young Jeong Yeji Jung Jaeyeon Jang Dae-Ho Choi Joohyun Hong Hyo Jung Kim Soo Youn Cho Yeon Hee Park |
| author_sort | Youngkyung Jeon |
| collection | DOAJ |
| description | Background: The World Health Organization's fifth edition of tumor series classification was published in 2019 and adopted the term ‘Neuroendocrine neoplasm (NEN)’ to encompass all tumor classes with predominant neuroendocrine differentiation (NED). Based on the updated classification of the NEN, we conducted a case series using the Clinical Data Warehouse platform of SMC. Methods: In this retrospective study, breast NENs and invasive breast carcinomas no special type (IBCNST) with NED, were defined as 'NENS’. Based on pathology slide findings, a pathologist reclassified the diagnoses. Clinical presentation, tumor characteristics, and clinical outcomes of breast ‘NENS’ were reviewed retrospectively. Results: A total of 34,370 patients were diagnosed with breast cancer from 1995 to 2022 in SMC, and 14 (0.04 %) patients were diagnosed with breast ‘NENS’: eight NECs, three NETs, and three IBCNST with NED. The patients’ median age was 48.5 years. All patients were treated with curative intent surgery; five patients received neoadjuvant chemotherapy, twelve patients received radiotherapy, six patients received adjuvant chemotherapy, and eight patients received hormone therapy. The median follow-up period for the eight patients with breast NEC was 20.4 months. The median disease-free and overall survival were 14.2 months and 23.6 months, respectively. Patients with NET or IBCNST with NED (n = 6) had an overall favorable outcome, with no deaths, with only one case of disease recurrence. Conclusion: The incidence of primary breast NENS’ was very low (0.04 %) in this single-center study. Among them, primary breast NEC was associated with poor overall survival. Novel treatments are thus required to improve the prognosis of primary breast NEC. |
| format | Article |
| id | doaj-art-6ad05bc38c7845199191ff31b1426ff0 |
| institution | Kabale University |
| issn | 2468-2942 |
| language | English |
| publishDate | 2024-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Cancer Treatment and Research Communications |
| spelling | doaj-art-6ad05bc38c7845199191ff31b1426ff02025-02-09T05:00:46ZengElsevierCancer Treatment and Research Communications2468-29422024-01-0142100857Breast cancers with neuroendocrine differentiation: Retrospective case studies series from a single institution based on the 2019 WHO classificationYoungkyung Jeon0Ji-Yeon Kim1Jin Seok Ahn2Young-Hyuck Im3Kyuehee Choi4Sun Young Jeong5Yeji Jung6Jaeyeon Jang7Dae-Ho Choi8Joohyun Hong9Hyo Jung Kim10Soo Youn Cho11Yeon Hee Park12Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; Division of Medical Oncology and Hematology, Department of Internal Medicine, Pusan National University Yangsan Hospital, Pusan National University School of Medicine, Yangsan, Republic of KoreaDivision of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of KoreaDivision of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of KoreaDivision of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of KoreaDepartment of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of KoreaDivision of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of KoreaDivision of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of KoreaDivision of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of KoreaDivision of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of KoreaDivision of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of KoreaDepartment of Digital Health, Samsung Advanced Institute for Health Science & Technology, Sungkyunkwan University, Seoul, Republic of Korea; Research Institute for Future Medicine, Samsung Medical Center, Seoul, Republic of KoreaDepartment of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of KoreaDivision of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea; Corresponding author at: Division of Hematology and Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Republic of Korea.Background: The World Health Organization's fifth edition of tumor series classification was published in 2019 and adopted the term ‘Neuroendocrine neoplasm (NEN)’ to encompass all tumor classes with predominant neuroendocrine differentiation (NED). Based on the updated classification of the NEN, we conducted a case series using the Clinical Data Warehouse platform of SMC. Methods: In this retrospective study, breast NENs and invasive breast carcinomas no special type (IBCNST) with NED, were defined as 'NENS’. Based on pathology slide findings, a pathologist reclassified the diagnoses. Clinical presentation, tumor characteristics, and clinical outcomes of breast ‘NENS’ were reviewed retrospectively. Results: A total of 34,370 patients were diagnosed with breast cancer from 1995 to 2022 in SMC, and 14 (0.04 %) patients were diagnosed with breast ‘NENS’: eight NECs, three NETs, and three IBCNST with NED. The patients’ median age was 48.5 years. All patients were treated with curative intent surgery; five patients received neoadjuvant chemotherapy, twelve patients received radiotherapy, six patients received adjuvant chemotherapy, and eight patients received hormone therapy. The median follow-up period for the eight patients with breast NEC was 20.4 months. The median disease-free and overall survival were 14.2 months and 23.6 months, respectively. Patients with NET or IBCNST with NED (n = 6) had an overall favorable outcome, with no deaths, with only one case of disease recurrence. Conclusion: The incidence of primary breast NENS’ was very low (0.04 %) in this single-center study. Among them, primary breast NEC was associated with poor overall survival. Novel treatments are thus required to improve the prognosis of primary breast NEC.http://www.sciencedirect.com/science/article/pii/S2468294224000698Breast neoplasmNeuroendocrine tumorProgression-free survival |
| spellingShingle | Youngkyung Jeon Ji-Yeon Kim Jin Seok Ahn Young-Hyuck Im Kyuehee Choi Sun Young Jeong Yeji Jung Jaeyeon Jang Dae-Ho Choi Joohyun Hong Hyo Jung Kim Soo Youn Cho Yeon Hee Park Breast cancers with neuroendocrine differentiation: Retrospective case studies series from a single institution based on the 2019 WHO classification Cancer Treatment and Research Communications Breast neoplasm Neuroendocrine tumor Progression-free survival |
| title | Breast cancers with neuroendocrine differentiation: Retrospective case studies series from a single institution based on the 2019 WHO classification |
| title_full | Breast cancers with neuroendocrine differentiation: Retrospective case studies series from a single institution based on the 2019 WHO classification |
| title_fullStr | Breast cancers with neuroendocrine differentiation: Retrospective case studies series from a single institution based on the 2019 WHO classification |
| title_full_unstemmed | Breast cancers with neuroendocrine differentiation: Retrospective case studies series from a single institution based on the 2019 WHO classification |
| title_short | Breast cancers with neuroendocrine differentiation: Retrospective case studies series from a single institution based on the 2019 WHO classification |
| title_sort | breast cancers with neuroendocrine differentiation retrospective case studies series from a single institution based on the 2019 who classification |
| topic | Breast neoplasm Neuroendocrine tumor Progression-free survival |
| url | http://www.sciencedirect.com/science/article/pii/S2468294224000698 |
| work_keys_str_mv | AT youngkyungjeon breastcancerswithneuroendocrinedifferentiationretrospectivecasestudiesseriesfromasingleinstitutionbasedonthe2019whoclassification AT jiyeonkim breastcancerswithneuroendocrinedifferentiationretrospectivecasestudiesseriesfromasingleinstitutionbasedonthe2019whoclassification AT jinseokahn breastcancerswithneuroendocrinedifferentiationretrospectivecasestudiesseriesfromasingleinstitutionbasedonthe2019whoclassification AT younghyuckim breastcancerswithneuroendocrinedifferentiationretrospectivecasestudiesseriesfromasingleinstitutionbasedonthe2019whoclassification AT kyueheechoi breastcancerswithneuroendocrinedifferentiationretrospectivecasestudiesseriesfromasingleinstitutionbasedonthe2019whoclassification AT sunyoungjeong breastcancerswithneuroendocrinedifferentiationretrospectivecasestudiesseriesfromasingleinstitutionbasedonthe2019whoclassification AT yejijung breastcancerswithneuroendocrinedifferentiationretrospectivecasestudiesseriesfromasingleinstitutionbasedonthe2019whoclassification AT jaeyeonjang breastcancerswithneuroendocrinedifferentiationretrospectivecasestudiesseriesfromasingleinstitutionbasedonthe2019whoclassification AT daehochoi breastcancerswithneuroendocrinedifferentiationretrospectivecasestudiesseriesfromasingleinstitutionbasedonthe2019whoclassification AT joohyunhong breastcancerswithneuroendocrinedifferentiationretrospectivecasestudiesseriesfromasingleinstitutionbasedonthe2019whoclassification AT hyojungkim breastcancerswithneuroendocrinedifferentiationretrospectivecasestudiesseriesfromasingleinstitutionbasedonthe2019whoclassification AT sooyouncho breastcancerswithneuroendocrinedifferentiationretrospectivecasestudiesseriesfromasingleinstitutionbasedonthe2019whoclassification AT yeonheepark breastcancerswithneuroendocrinedifferentiationretrospectivecasestudiesseriesfromasingleinstitutionbasedonthe2019whoclassification |